Unknown

Dataset Information

0

Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study.


ABSTRACT: The worldwide rapid spread of the COVID-19 disease necessitates the search for fast and effective treatments. The repurposing of existing drugs seems to be the best solution in this situation. In this study, the molecular docking method was used to test 248 drugs against the receptor-binding domain (RBD) of spike glycoprotein of SARS-CoV-2, which is responsible for viral entry into the host cell. Among the top-ranked ligands are drugs that are used for hepatitis C virus (HCV) treatments (paritaprevir, ledipasvir, simeprevir) and a natural biflavonoid amentoflavone. The binding sites of the HCV drugs and amentoflavone are different. Therefore, the ternary complexes of the HCV drug, amentoflavone, and RBD can be created. For the 5 top-ranked ligands, the validating molecular dynamics simulations of binary and ternary complexes with RBD were performed. According to the MMPBSA-binding free energies, the HCV drugs ledipasvir and paritaprevir (in a neutral form) are the most efficient binders of the RBD when used in combination with amentoflavone.Communicated by Ramaswamy H. Sarma.

SUBMITTER: Miroshnychenko KV 

PROVIDER: S-EPMC8074653 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study.

Miroshnychenko Kateryna V KV   Shestopalova Anna V AV  

Journal of biomolecular structure & dynamics 20210426 19


The worldwide rapid spread of the COVID-19 disease necessitates the search for fast and effective treatments. The repurposing of existing drugs seems to be the best solution in this situation. In this study, the molecular docking method was used to test 248 drugs against the receptor-binding domain (RBD) of spike glycoprotein of SARS-CoV-2, which is responsible for viral entry into the host cell. Among the top-ranked ligands are drugs that are used for hepatitis C virus (HCV) treatments (paritap  ...[more]

Similar Datasets

| S-EPMC7645152 | biostudies-literature
| S-EPMC8421753 | biostudies-literature
2007-12-01 | GSE9732 | GEO
| S-EPMC7691136 | biostudies-literature
| S-EPMC7649901 | biostudies-literature
| S-EPMC8406544 | biostudies-literature
| S-EPMC8660130 | biostudies-literature
| S-EPMC7834737 | biostudies-literature
2010-05-22 | E-GEOD-9732 | biostudies-arrayexpress
| S-EPMC7876913 | biostudies-literature